Lymphomas in 2024 Changing Standards of Care and Challenging Paradigms Elizabeth Brem, MD from UCI

Elizabeth Brem, MD, - UCI Health discusses the treatment of lymphomas, including Hodgkin lymphoma and diffuse large B-cell lymphoma, is experiencing a pivotal shift towards personalized and more effective strategies due to the integration of novel therapeutic agents such as brentuximab vedotin, nivolumab, polatuzumab vedotin, and bispecific antibodies. This evolution in clinical practice, led by oncologists, aims to significantly improve patient outcomes and quality of life by adapting these advancements into care protocols. The ongoing research and development in oncology highlight the importance of keeping current with these innovations to continue enhancing patient care in the realm of lymphoma treatment.